Elaine Chen
Senior Scientist, Translational Biology Rondo Therapeutics
Elaine Chen is a Senior Scientist at Rondo Therapeutics, where she develops bispecific antibodies for the treatment of solid tumors. With expertise spanning discovery and translational biology, she has contributed to antibody therapeutic programs across oncology, immunology, and virology. She has led multiple therapeutic programs from early discovery through lead optimization, driving candidates toward development milestones. At Rondo, she has led antibody discovery efforts and now supports the translational biology team in advancing the company’s first molecule toward the clinic. Elaine earned her PhD from Vanderbilt University under Dr. James E. Crowe, where she combined experimental and computational approaches to study human B-cell repertoires in survivors of infectious diseases.
Seminars
- Developing a suite of CD28 agonistic antibodies optimized for bispecific engineering to target solid tumors
- Addressing the limited translation of transformative outcomes of T-cell engagers in hematologic cancers, into solid tumors
- Integrating CD28 costimulation into bispecific therapeutics to enhance T-cell effector function and drive robust anti-tumor responses in the solid tumor setting
